FICT vs Chemiluminescence: Where Each Method Belongs
Quick Answer — Chemiluminescence is the stronger analytical technique in absolute terms: brighter signal, lower background, very low detection limits, and a menu that suits a central laboratory. Fluorescence immunochromatography gives up some of that headroom in exchange for portability, speed and single-sample economics. The question is not which is better, but which constraint binds in your setting — detection limit or latency.
The comparison
| Dimension | Chemiluminescence | FICT |
|---|---|---|
| Signal | Light emission from a chemical reaction | Fluorescence from labelled microspheres |
| Limit of detection | Often lower | Adequate for most clinical thresholds |
| Platform size and cost | Large, expensive | Bench-top |
| Throughput model | High-volume batch | Single sample, on demand |
| Turnaround | Minutes to hours, plus transport | Minutes |
| Menu breadth | Typically wider | Focused veterinary menu |
| Operator complexity | Higher — reagents, maintenance | Low |
| Site | Central laboratory | Clinic, shelter, field |
The sensitivity question, asked honestly
A lower LoD is a real capability, and there are analytes where it changes clinical decisions — cardiac markers and some hormones being the usual examples. But for many veterinary markers the decision threshold sits orders of magnitude above either method’s detection limit, which means the sensitivity difference has no clinical consequence.
Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.
A vendor who claims superior sensitivity without locating the decision threshold is making an analytical claim, not a clinical one.
Where each method fits
Chemiluminescence: central reference laboratories; high-volume panels; research settings requiring traceable low-end performance; analytes where the clinical question is genuinely at the low end of the range.
FICT: clinics making same-visit decisions; shelters and outbreak settings; mobile practice; any case where a result tomorrow would arrive after the decision point.
The latency argument, quantified
The trade is usually framed as sensitivity versus convenience. The more useful framing is: what is the cost of waiting?
| Situation | Cost of a 24-hour delay |
|---|---|
| Suspect parvovirus in a shelter | Cohort exposure for another day |
| Breeding timing decision | A cycle lost |
| Dyspnoeic cat triage | Empirical treatment started blind |
| Post-operative monitoring | Complication identified a day later |
Where that cost is high, a method with a slightly higher LoD and a same-hour result is the better clinical instrument. Where the cost is low — routine screening, research endpoints — the more sensitive method wins.
Comparability warning
The two methods do not produce interchangeable numbers. Different calibration systems and signal-to-concentration relationships produce proportional bias, and a decision limit from a chemiluminescence platform applied to a fluorescence result will misclassify.
Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.
Six traps
- Treating LoD as clinical sensitivity. They are different.
- Importing decision limits across methods. Systematic misclassification.
- Ignoring latency cost. The most common analytical-efficiency mistake.
- Comparing menus by count rather than by relevance. A wider menu with unused assays is not an advantage.
- Assuming central-lab precision transfers to point of care. Handling and operator differ.
- Ignoring maintenance burden. A high-end platform that is not maintained underperforms a simple one.
The Author’s Take
Position. In this comparison, the point-of-care vendor should concede the analytical argument and win the clinical one — because that is the only version that survives scrutiny.
Reasoning. A laboratory scientist will not accept that a bench-top cartridge matches a chemiluminescence platform on detection limit, and pretending otherwise ends the conversation. What that scientist will accept is that the decision limit for most veterinary analytes sits well above both, and that the binding constraint in practice is turnaround. That argument is checkable, it respects the buyer’s expertise, and it moves the discussion from method prestige to clinical workflow — which is the ground where point-of-care testing actually wins.
Disclosure. This page compares method categories, not specific products. Figures marked indicate where platform-specific detection limits and comparison data must be inserted.
Sources
- Reference to be added.
- CLSI EP17 — detection capability.
- Reference to be added.
Frequently asked questions
- Is chemiluminescence more sensitive than fluorescence immunochromatography?
- Chemiluminescence platforms can achieve very low limits of detection because of signal amplification and optimised optics, at the cost of size, cost and complexity. Whether the difference matters clinically depends on the analyte: for many veterinary markers, the decision threshold sits far above either method's limit of detection.
- When does chemiluminescence make more sense?
- At high volume in a central laboratory, where batch throughput, very low detection limits and a wide menu justify the platform cost. For a clinic making same-hour decisions, the practical advantage usually goes to the point-of-care method, because latency dominates.
- Can results from the two methods be compared?
- Not directly. Different calibration and signal systems produce proportional bias, so reference intervals and decision limits do not transfer. Any switch requires method comparison and new intervals.